International Ophthalmology

, Volume 38, Issue 3, pp 1129–1134 | Cite as

Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent

  • Alessandra De Gregorio
  • Emilio Pedrotti
  • Luisa Russo
  • Simonetta Morselli
Original Paper



To verify the efficacy in intraocular pressure (IOP) reduction and safety of the smallest gel stent (XEN 45 Gel Stent) microincisional glaucoma surgery combined with microincisional cataract surgery (MICS).


Nonrandomized prospective clinical study. Forty-one eyes of 33 patients with open-angle glaucoma underwent a XEN 45 Gel Stent implantation combined with MICS. Treatment outcomes analyzed included: IOP, medication use, intra- and postoperative complications. At the end of the follow-up, we evaluated the complete success, defined as a postoperative IOP ≥ 6 and ≤17 mmHg without glaucoma medications and the qualified success defined as a postoperative IOP ≥ 6 and ≤17 mmHg, with glaucoma medications.


The mean preoperative IOP was 22.5 ± 3.7 mmHg on 2.5 ± 0.9 medication classes. After 12 months, the mean postoperative IOP was 13.1 ± 2.4 mmHg (mean IOP reduction of 41.82%) with a mean of 0.4 ± 0.8 medication classes (P < 0.05 for IOP and medications). The complete success rate was achieved in 80.4% and a qualified success in 97.5%. There were no major intra- and postoperative complications during the first year of follow-up.


This study demonstrated that the smaller diameter XEN 45 gel implant is statistically effective in reducing IOP and medications in glaucoma patients with a low rate of complications.


Glaucoma Microincisional glaucoma surgery (MIGS) XEN Gel Stent Filtration surgery 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013 CrossRefPubMedGoogle Scholar
  2. 2.
    Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M (2002) Early manifest glaucoma trial group. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 120:1268–1279CrossRefPubMedGoogle Scholar
  3. 3.
    Lewis RA (2014) Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J Cataract Refract 40:1301–1306. doi: 10.1016/j.jcrs.2014.01.032 CrossRefGoogle Scholar
  4. 4.
    Watson PG, Jakemn C, Ozturk M, Barnett F, Khaw KT (1990) The complications of trabeculectomy (20 year follow-up). Eye 4:425–438. doi: 10.1038/eye.1990.54 CrossRefPubMedGoogle Scholar
  5. 5.
    Nouri-Mahdavi K, Brigatti L, Weitzman M, Caprioli J (1995) Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology 102:1760–1769. doi: 10.1016/S0161-6420(95)30796-8 CrossRefPubMedGoogle Scholar
  6. 6.
    Mosaed S, Dustin L, Minckler DS (2009) Comparative outcomes between newer and older surgeries for glaucoma. Trans Am Ophthalmol Soc 107:127–133PubMedPubMedCentralGoogle Scholar
  7. 7.
    Saheb H, Ahmed II (2012) Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 23(2):96–104. doi: 10.1097/ICU.0b013e32834ff1e7 CrossRefPubMedGoogle Scholar
  8. 8.
    Richter GM, Coleman AL (2016) Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophtalmol 10:189–206. doi: 10.2147/OPTH.S80490 Google Scholar
  9. 9.
    Sheybani A, Reitsamer H, Ahmed II (2015) Fluid dynamics of a novel micro-fistula implant for the surgical treatment of glaucoma. Invest Ophthalmol Vis Sci 56(8):4789–4795. doi: 10.1167/iovs.15-16625 CrossRefPubMedGoogle Scholar
  10. 10.
    Sheybani A, Dick B, Ahmed IIK (2015) Early clinical results of a novel ab interno gel stent for the surgical treatment of open-angle glaucoma. J Glaucoma 00:1–6. doi: 10.1097/IJG.0000000000000352 Google Scholar
  11. 11.
    Sheybani A, Lenzhofer M, Hohensinn M, Reitsamer H, Ahmed IIK (2015) Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: pilot study. J Cataract Refract Surg 41:1905–1909. doi: 10.1016/j.jcrs.2015.01.019 CrossRefPubMedGoogle Scholar
  12. 12.
    Shaarawy T, Sherwood MB, Grehn F (2009) Guidelines on design and reporting of glaucoma surgical trials. Kugler Publications, AmsterdamGoogle Scholar
  13. 13.
    Singh D (2003) Conjunctiva lymphatic system. J Cataract Refract Surg 29:632–633. doi: 10.1155/2012/783163 CrossRefPubMedGoogle Scholar
  14. 14.
    Yu DY, Morgan WH, Sun X, Su EN, Cringle SJ, Yu PK, House P, Guo W, Yu X (2009) The critical role of the conjunctiva in glaucoma filtration surgery. Progr Retin Eye Res 29:303–328CrossRefGoogle Scholar
  15. 15.
    Shute TS, Dietrich UM, Dietrich UM, Baker JF, Carmichael KP, Wustenberg W, Ahmed II, Sheybani A (2016) Biocompatibility of a novel microfistula implant in nonprimate mammals for the surgical treatment of glaucoma. Invest Ophthalmol Vis Sci 57(8):3594–3600. doi: 10.1167/iovs.16-19453 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Ophthalmic UnitSan Bassiano HospitalBassano del GrappaItaly
  2. 2.Eye Clinic, Department of Neuroscience, Biomedicine and MovementUniversity of VeronaVeronaItaly

Personalised recommendations